Ginkgo's Head of Protein Engineering shares how the foundry makes it possible to generate the valuable data that drives enzyme discovery and optimization.

Artificial intelligence models are learning to speak the language of proteins, changing the ways scientists ask questions about biology. In this panel, we’ll hear from experts who are building these AI models and leveraging them for innovation in pharma and other applications. They discuss how AI is fundamentally changing the way we approach science and how it translates into the world.

There are as many applications of synthetic biology as there are cell developers dreaming up new possibilities. Hear from these developers using the Ginkgo platform to build sustainable, optimized, or entirely new classes of products.

Ginkgo's Head of Agricultural Biologicals covers how innovators can address the challenges grower's face in today's world, leveraging Ginkgo's platform to discover new traits and optimize for performance and consistency.

What if there were a technology that could draw down carbon, manufacture durable materials, and feed the world? Traditional players in agriculture as well as innovative new startups are exploring creative approaches to plant and microbe engineering to address global challenges in climate and agriculture.

There are as many applications of synthetic biology as there are cell developers dreaming up new possibilities. Hear from these developers using the Ginkgo platform to build sustainable, optimized, or entirely new classes of products.

Senior Director of Mammalian Engineering shares an overview of how Ginkgo's services can help those innovating new medicines address patient needs for greater efficacy, specificity, and access to emerging modalities.

Renee Wegrzyn, the inaugural Director of the Advanced Research Projects Agency for Health (ARPA-H), is on a mission to change how innovation happens in health and medicine. By bringing the innovation catalyst mindset from DARPA to biology, Renee shares how ARPA-H empowers innovators, embraces failures, and pushes the world of health and medicine to think bigger than ever before.

There are as many applications of synthetic biology as there are cell developers dreaming up new possibilities. Hear from these developers using the Ginkgo platform to build sustainable, optimized, or entirely new classes of products.

Ginkgo's General Manager for Biosecurity highlights progress towards building a global "radar system" for biological threats.

As demonstrated during the COVID-19 pandemic, synthetic biology is an essential tool in building more resilient systems of public health that can monitor, detect, and respond to pathogen threats. What lessons have we learned from the pandemic, and what is the vision for a biosecurity infrastructure that serves the emerging bioeconomy and manages the risk and impact of infectious disease?

Cell and gene therapy breakthroughs now offer promise to patients with intractable diseases. Patients need access to these novel approaches – but introducing new modalities is incredibly challenging to pharmaceutical companies due to technical, regulatory, and commercial risks. Alnylam founder John Maraganore navigated this complexity when bringing siRNA therapeutics from the lab to patients. In this fireside chat, John offers his insights to companies that are bringing new technologies to scale.

Stories from Grow Magazine, adapted for the stage with music, animation, and performance.